Detalhe da pesquisa
1.
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL.
Blood
; 142(13): 1131-1142, 2023 09 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37363833
2.
Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial.
Lancet Oncol
; 25(4): 463-473, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467131
3.
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(6): 818-828, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654052
4.
The idiopathic preterm delivery methylation profile in umbilical cord blood DNA.
BMC Genomics
; 16: 736, 2015 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-26419829
5.
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial.
Lancet Haematol
; 9(3): e190-e199, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35240075
6.
PRRT2-related phenotypes in patients with a 16p11.2 deletion.
Eur J Med Genet
; 62(4): 265-269, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30125676
7.
The importance of chromosome studies in Roberts syndrome/SC phocomelia and other cohesinopathies.
Eur J Med Genet
; 53(1): 40-4, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19878742